T1	Premise 668 743	Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).
T2	Premise 744 891	ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.
T3	Premise 892 992	No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
T4	Premise 993 1036	No unexpected adverse events were observed.
T5	Premise 1037 1614	Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.
T6	Claim 1615 1715	This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
T7	Claim 1716 1808	Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)
T8	Claim 1809 1867	the overall toxicity profile of vinflunine was manageable.
T9	MajorClaim 1879 1966	VFL may be another option in the second-line treatment of patients with advanced NSCLC.
R1	Partial-Attack Arg1:T7 Arg2:T8	
R2	Support Arg1:T8 Arg2:T9	
R3	Support Arg1:T6 Arg2:T9	
R4	Support Arg1:T4 Arg2:T8	
R5	Support Arg1:T5 Arg2:T7	
R6	Support Arg1:T3 Arg2:T6	
R7	Support Arg1:T2 Arg2:T6	
R8	Support Arg1:T1 Arg2:T6	
